Other
Relapsed/refractory
2
Pipeline Programs↗
71
Active Trials↗
37
Companies Involved↗
Relapsed/Refractory is an early-stage landscape with 2 programs across 37 companies. The most active players are TJ Biopharma Co., Ltd., Regeneron, Chongqing Precision Biotech Co., Ltd. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Approved
No programs
Analysis
Trial Status
171
clinical trials
Recruiting44 · 26%
Completed43 · 25%
Unknown status29 · 17%
Active, not recruiting16 · 9%
Terminated15 · 9%
Not yet recruiting11 · 6%
Other13 · 8%
Clinical Trials
Trial Activity
171 trials
Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
Recruiting·SShanghai Tongji Hospital, Tongji University School of Medicine·Phase 1·NCT06375161·12 enrolled
Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA
Recruiting·—·Phase 2·NCT05922839·22 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)